通过改善喷射分数来治疗心力衰竭:当前的证据和争议
Nandan Kodur1, W H Wilson Tang2
1Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
JACC. Heart failure
|April 9, 2025
概括
心力衰竭改善排气分数 (HFimpEF) 患者可以安全地减少指导方针导向医学治疗 (GDMT),如果他们的心力衰竭是由于急性原因而完全消失的. 需要进一步的研究来确定哪些患者可以安全地缓解治疗.
科学领域:
- 心脏病学 心脏病学
- 心脏衰竭研究研究
- 临床医学 临床医学
背景情况:
- 改善喷射率 (HFimpEF) 的心力衰竭的特点是左心室喷射率 (LVEF) 从降低的基线恢复.
- 由于复发和不良事件的风险,目前的指导方针要求所有HFimpEF患者进行无限期的指导方针导向医学治疗 (GDMT).
- 新出现的证据表明,HFimpEF患者的一个子集,特别是那些急性和完全解决病因的患者,可能有更有利的预后.
研究的目的:
- 探索在选择的HFimpEF患者中降低GDMT升级的潜力.
- 确定恢复LVEF的患者风险分层的潜在方法.
- 在特定的HFimpEF人群中调查减少或停止GDMT和植入式心脏转换器-除器治疗的安全性和可行性.
主要方法:
- 审查新兴的临床经验和队列/病例系列研究.
- 在患有特定急性心力衰竭病因的患者中,分析GDMT降级的可行性.
- 确定未来研究的领域,包括先进的成像,生物标志物和设备治疗的停止.
主要成果:
- 队列和病例系列研究表明,在精选的HFimpEF患者中,完全解决了急性病因,安全的GDMT降级是可行的.
- 目前,多个小型临床试验正在研究这种治疗方法.
- 需要进一步研究风险分层工具和降级先进疗法的安全性.
结论:
- 降低GDMT的升级可能是对精心挑选的HFimpEF患者的安全和可行的选择,特别是那些急性心力衰竭患者.
- 未来的研究应该专注于先进的成像,生物标志物和临床试验数据,以指导个性化治疗策略.
- 安全停止GDMT和植入式心脏转换器-除器治疗的潜力需要进一步调查,以优化患者护理和减少治疗负担.
更多相关视频
相关概念视频
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
329
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329
01:22Heart Failure Drugs: Diuretics
298
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298
01:22Heart Failure Drugs: β-Blockers
284
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
284
01:26Imbalances in Cardiac Output
1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.2K
01:26Heart Failure Drugs: Inotropic Agents
440
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
440